Valneva’s (VALN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Valneva (NASDAQ:VALN) in a research report report published on Friday,Benzinga reports. They currently have a $17.00 price objective on the stock.

Valneva Stock Down 1.1 %

VALN stock opened at $7.17 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business’s 50 day simple moving average is $6.34 and its 200 day simple moving average is $5.58. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50. The firm has a market capitalization of $582.64 million, a PE ratio of -55.15 and a beta of 1.93.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The firm had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. As a group, research analysts anticipate that Valneva will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA bought a new stake in shares of Valneva SE (NASDAQ:VALN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.